Damora Therapeutics (DMRA) Change in Cash (2019 - 2026)

Damora Therapeutics' Change in Cash history runs 8 years deep, the most recent figure standing at $275.3 million for Q1 2026.

• Quarterly Change in Cash rose 11388.36% year-over-year to $275.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $520.5 million (up 5803.55% YoY) and the FY2025 annual result came in at $242.7 million, up 3581.2% from the prior year.
• Change in Cash was $275.3 million for Q1 2026 at Damora Therapeutics, up from $250.0 million in the prior quarter.
• Across five years, Change in Cash topped out at $275.3 million in Q1 2026 and bottomed at -$17.0 million in Q1 2022.
• A 5-year average of $27.6 million and a median of -$2.1 million in 2023 frame the typical range for Change in Cash.
• Annual changes were most pronounced in 2024 — Change in Cash sank 182650.0% — and 2026, when it soared 11388.36%.
• Damora Therapeutics' Change in Cash stood at $2.9 million in 2022, then plunged by 164.27% to -$1.9 million in 2023, then tumbled by 160.61% to -$4.9 million in 2024, then surged by 5165.56% to $250.0 million in 2025, then grew by 10.11% to $275.3 million in 2026.
• Business Quant data shows DMRA's Change in Cash at $275.3 million in Q1 2026, $250.0 million in Q4 2025, and -$2.6 million in Q3 2025.